DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 391

24. Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. 2000. Hepatic transport of bile
salts. Semin Liver Dis 20(3):273-292.
25. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. 2005. Bile salt export pump
(BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp
Ther 314(2):876-882.
26. Kullak-Ublick GA, Stieger B, Meier PJ. 2004. Enterohepatic bile salt transporters in
normal physiology and liver disease. Gastroenterology 126(1):322-342.
27. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. 2001.
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a
potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223-
231.
28. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R. 2001.
Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary
export of bile acids in male and female rats. Correlation with the gender difference
in troglitazone sulfate formation and the inhibition of the canalicular bile salt ex-
port pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167(1):83-
98.
29. Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D. 1999. Exon-intron
organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in
Dubin-Johnson syndrome. Gastroenterology 117(3):653-660.
30. Konig J, Rost D, Cui Y, Keppler D. 1999. Characterization of the human multidrug
resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.
Hepatology 29(4):1156-1163.
31. Kuroda M, Kobayashi Y, Tanaka Y, Itani T, Mifuji R, Araki J, Kaito M, Adachi Y. 2004.
Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in
Eisai hyperbilirubinuria rats. J Gastroenterol Hepatol 19(2):146-153.
32. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC,
Ruevekamp-Helmers MC, Floot BG, Schellens JH. 1999. Overexpression of the
BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res
59(18):4559-4563.
33. Borst P, Evers R, Kool M, Wijnholds J. 1999. The multidrug resistance protein family.
Biochim Biophys Acta 1461(2):347-357.
34. Hirohashi T, Suzuki H, Sugiyama Y. 1999. Characterization of the transport prop-
erties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem
274(21):15181-15185.
35. Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH,
Schuetz JD. 2002. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS
PharmSci 4(3):E14.
36. Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. 2003.
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein
(MRP) 4 (ATP-binding cassette C4). Biochem J 371(Pt 2):361-367.
37. Donner MG, Warskulat U, Saha N, Haussinger D. 2004. Enhanced expression of
basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS.
Biol Chem 385(3-4):331-339.
38. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. 2000. Drug- and
estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export
pump (Bsep) of rat liver. Gastroenterology 118(2):422-430.